Pre-earnings options volume in Cidara Therapeutics is 2.2x normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 14.0%, or 0c, after results are released. Median move over the past eight quarters is 2.7%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CDTX:
- Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress
- Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock
- Cidara Therapeutics options imply 20.0% move in share price post-earnings
- Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
- Cidara Therapeutics 11.8M share Spot Secondary priced at $1.40